Inspire (INSP) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts forecast that Inspire Medical Systems (INSP) will report quarterly earnings of $0.69 per share in its upcoming release, pointing to a year-over-year decline of 40%. It is anticipated that revenues will amount to $269 million, exhibiting an increase of 12.2% compared to the year-ago quarter.

Over the last 30 days, there has been a downward revision of 28.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

That said, let's delve into the average estimates of some Inspire metrics that Wall Street analysts commonly model and monitor.

The collective assessment of analysts points to an estimated 'Geographic Revenue- United States' of $255.18 million. The estimate points to a change of +10.2% from the year-ago quarter.

The consensus estimate for 'Geographic Revenue- All other countries' stands at $10.63 million. The estimate indicates a year-over-year change of +31.5%.

It is projected by analysts that the 'Total U.S. sales territories' will reach 342 . Compared to the current estimate, the company reported 335 in the same quarter of the previous year.

View all Key Company Metrics for Inspire here>>>

Over the past month, Inspire shares have recorded returns of -31.6% versus the Zacks S&P 500 composite's no change. Based on its Zacks Rank #3 (Hold), INSP will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Just Released: Zacks Top 10 Stocks for 2026

Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.

From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.

Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Inspire Medical Systems, Inc. (INSP): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research